OUR APPROACH
OUR APPROACH
Cytospire is developing an innovative portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells.
Gamma delta T cells
Gamma delta T cells combine the immediate potency of innate immunity with the coordination of a long lasting adaptive immune response. Their mechanism of recognition provides gamma delta T cells with the ability to exquisitely discriminate between target diseased vs healthy cells (1).
Gamma delta T cells comprise both blood resident and tissue/tumour resident subtypes. Others are bringing forward subtype specific gamma delta T cell and engager therapies.
Cytospire’s unique approach makes us the only company currently developing antibodies able to target all gamma delta T cells, both blood and tissue resident.
This differentiated technology enables us to stimulate a critical mass of gamma delta T cells and removes the complexity of heterogeneity between patients in gamma delta T cell subtype numbers.
A new approach to treating solid tumours
The importance of gamma delta T cells in the immune response to cancer is well known. Many studies have shown that patients with a range of tumour types who have a healthy population of gamma delta T cells have a better prognosis (2-6).
Cytospire’s first in class multispecific gamma delta engagers are uniquely positioned to provide a solution for solid tumours:
- Activation of tissue/tumour resident as well as blood resident gamma delta T cells
- Potent killing of tumour cells whilst sparing healthy cells
- Low risk of cytokine related adverse events
Our approach represents a new wave in next generation immune cell engagers which have the potential to benefit patients who are poorly served by current therapies.
References:
(1) Mensurado, S et al. Nature Reviews. Clinical Oncology, 20, 178-191 (2023)
(2) Foord, E. et al., Science Translational Medicine, Vol 13, Issue 577 (2021)
(3) de Vries, N.L. et al., Nature 613, 743-750 (2023)
(4) Wu, Y. et al. Science Translational Medicine, Vol 11, Issue 513 (2019)
(5) Gentles, A. J. et al. Nature Medicine 21, 938-945 (2015)
(6) Wu, Y. et al. Nature Cancer 3, 696-709 (2022)
